Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Authors:
Open Access
- 9 December 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (1) , 4-11
Abstract
OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m2) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight. RESULTS: Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (−7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (−2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss. CONCLUSIONS: Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment.Keywords
This publication has 25 references indexed in Scilit:
- Is the GLP-1 system a viable therapeutic target for weight reduction?Reviews in Endocrine and Metabolic Disorders, 2011
- Present and Future: Pharmacologic Treatment of ObesityJournal of Obesity, 2011
- The Cardiovascular Effects of GLP‐1 Receptor AgonistsCardiovascular Therapeutics, 2010
- Adaptive thermogenesis in humansInternational Journal of Obesity, 2010
- Bariatric surgery: Mechanisms, indications and outcomesJournal of Gastroenterology and Hepatology, 2010
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort DatabaseDiabetes Care, 2010
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-DiabetesDiabetes Care, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and CarbohydratesNew England Journal of Medicine, 2009
- Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietNew England Journal of Medicine, 2008